MAIN RESULTS: Combining the results of five randomised clinical trials randomising 499 patients with alcoholic hepatitis and/or cirrhosis demonstrated no significant effects of anabolic-androgenic steroids on mortality (relative risk (RR) , 95% confidence interval (CI) to ), liver-related mortality (RR , 95% CI to ), complications of liver disease (RR , 95% CI to ), and liver histology. Anabolic-androgenic steroids did not significantly affect a number of other outcome measures, including sexual function and liver biochemistry. Anabolic-androgenic steroids were not associated with a significantly increased risk of non-serious adverse events (RR , 95% CI to ) or with serious adverse events (RR , 95% CI to ).
Good article. Just started my first cycle of 2units/day gh mixed with the 350mg/week trt that I have taken for a couple years. I’m 26 and opposite of what the article points out about young males; I have noticed extremely favorable results in a matter of 6 weeks. My body fat was not high to begin with but I’ve already regained the majority of the muscle and abs I had in college during big cycles of test and an extremely active lifestyle / gym routine. All this without lifting a single lb of weights or doing one sit up. I sit at my desk all day and drink beers every evening. Im not sure if it has even fully started to kick in because it gets more noticeable everyday. Looking forward to seeing where this one takes me! If you’re on the fence, I’d say stay away from the roids and go hgh. Just my opinion!
Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks ) and deaths based on three peer-reviewed studies involving men taking testosterone replacement.  In addition, an increase of 30% in deaths and heart attacks in older men has been reported.  Due to an increased incidence of adverse cardiovascular events compared to a placebo group , a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee .  On January 31, 2014, reports of strokes , heart attacks , and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue.  Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT).    The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism .